The findings hold promise for the development of novel targeted therapies with fewer harmful side effects. (sciencedaily.com)
These results, which also include work from Akita University, Japan, and contributions from GSK could help to identify patients likely to benefit from novel targeted therapies. (sciencedaily.com)
Furthermore; novel targeted therapies with MAPK pathway kinase inhibitors (KIs) have been developed thanks to the discovery that BRAF and NRAS mutations which are among the major oncogenic drivers of melanoma proliferation and survival [12]. (jbiomed.com)